What is the current stock price of Lyell Immunopharma, Inc. (LYEL)?

As of the latest market data, Lyell Immunopharma, Inc. (LYEL) is trading at $17.46. The stock has seen a gain of 0.92% today.

Does Lyell Immunopharma, Inc. (LYEL) pay a dividend?

Based on current data, Lyell Immunopharma, Inc. does not have a confirmed active dividend policy.

What is the market cap of Lyell Immunopharma, Inc.?

The current market capitalization of Lyell Immunopharma, Inc. (LYEL) is approximately unavailable.

LYEL

Lyell Immunopharma, Inc.·Healthcare

17.46

0.925%(+0.16)

Market Closed

21.56

23.482%(+4.10)

After Hours

Last Updated: — ET

52W L: $7.6552W H: $45.00

LYEL NEWS

seekingalpha.com

11h ago

Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

seekingalpha.com

16h ago

Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

zacks.com

4d ago

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

globenewswire.com

May 12

Lyell Immunopharma Announces Participation in May Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences: H.C.

globenewswire.com

May 6

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosing Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3 Closed second $50 million tranche of $100 million private placement at $25.61 per share, with approximately $261 million in cash as of March 31, 2026, expected to provide runway into Q3 2027 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2026.

defenseworld.net

Apr 19

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Increase in Short Interest

Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares, an increase of 21.1% from the March 15th total of 940,269 shares. Currently, 6.3% of the company's stock are short sold. Based on an

Company Profile

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

300

IPO Date

2021-06-17

Beta

-0.06

Websitewww.lyell.com↗